Ashland Key Executives
This section highlights Ashland's key executives, including their titles and compensation details.
Find Contacts at Ashland
(Showing 0 of )
Ashland Earnings
This section highlights Ashland's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|---|---|---|---|---|
| Read Transcript | Q1 | 2025 | 2025-01-29 | N/A | N/A |
| Read Transcript | Q4 | 2024 | 2024-11-09 | N/A | N/A |
| Read Transcript | Q3 | 2024 | 2024-08-07 | N/A | N/A |
| Read Transcript | Q2 | 2024 | 2024-05-01 | N/A | N/A |
| Read Transcript | Q1 | 2024 | 2024-01-31 | N/A | N/A |
| Read Transcript | Q4 | 2023 | 2023-11-09 | N/A | N/A |
| Read Transcript | Q3 | 2023 | 2023-07-26 | N/A | N/A |
| Read Transcript | Q2 | 2023 | 2023-05-03 | N/A | N/A |
| Read Transcript | Q1 | 2023 | 2023-02-01 | N/A | N/A |
Ashland Inc. provides additives and specialty ingredients worldwide. It operates through Life Sciences; Personal Care & Household; Specialty Additives; and Intermediates and Solvents segments. The Life Sciences segment offers pharmaceutical solutions, including controlled release polymers, disintegrants, tablet coatings, thickeners, solubilizers, and tablet binders; nutrition solutions, such as thickeners, stabilizers, emulsifiers, and additives; and nutraceutical solutions comprising products for weight management, joint comfort, stomach and intestinal health, sports nutrition, and general wellness, as well as custom formulation, toll processing, and particle engineering solutions. The Personal Care & Household segment provides a range of nature-based, biodegradable, and performance ingredients; solutions for toothpastes, mouth washes and rinses, denture cleaning, and care for teeth; and household supplies nature-derived rheology ingredients, biodegradable surface wetting agents, performance encapsulates, and specialty polymers. The Specialty Additives segment offers rheology modifiers, foam control agents, surfactants and wetting agents, pH neutralizers, advanced ceramics used in catalytic converters, environmental filters, ingredients for the manufacturing of ceramic capacitors, plasma display panels and solar cells, ingredients for textile printing, thermoplastic metals, and alloys for welding. The Intermediates and Solvents segment produces 1,4 butanediol and related derivatives, including n-methylpyrrolidone. It offers its products to customers in a range of consumer and industrial markets, such as architectural coatings, construction, energy, food and beverage, nutraceuticals, personal care, and pharmaceutical. The company was formerly known as Ashland Global Holdings Inc. Ashland Inc. was founded in 1924 and is based in Wilmington, Delaware.
$56.93
Stock Price
$2.69B
Market Cap
3.20K
Employees
Wilmington, DE
Location
Financial Statements
Access annual & quarterly financial statements for Ashland, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | September 30, 2024 | September 30, 2023 | September 30, 2022 | September 30, 2021 | September 30, 2020 |
|---|---|---|---|---|---|
| Revenue | $2.11B | $2.19B | $2.39B | $2.11B | $2.33B |
| Cost of Revenue | $1.50B | $1.52B | $1.56B | $1.44B | $1.62B |
| Gross Profit | $618.00M | $668.00M | $830.00M | $670.00M | $707.00M |
| Gross Profit Ratio | 29.25% | 30.50% | 34.71% | 31.70% | 30.40% |
| Research and Development Expenses | $55.00M | $51.00M | $55.00M | $50.00M | $64.00M |
| General and Administrative Expenses | $404.00M | $363.00M | $391.00M | $357.00M | $422.00M |
| Selling and Marketing Expenses | $- | $2.00M | $2.00M | $1.00M | $2.00M |
| Selling General and Administrative Expenses | $404.00M | $365.00M | $393.00M | $358.00M | $424.00M |
| Other Expenses | $- | $-6.00M | $94.00M | $90.00M | $85.00M |
| Operating Expenses | $644.00M | $509.00M | $542.00M | $498.00M | $573.00M |
| Cost and Expenses | $2.14B | $2.03B | $2.10B | $1.94B | $2.19B |
| Interest Income | $- | $12.00M | $4.00M | $1.00M | $1.00M |
| Interest Expense | $43.00M | $6.00M | $62.00M | $69.00M | $88.00M |
| Depreciation and Amortization | $274.00M | $300.00M | $308.00M | $295.00M | $284.00M |
| EBITDA | $360.00M | $517.00M | $580.00M | $503.00M | $-202.00M |
| EBITDA Ratio | 17.04% | 18.39% | 20.37% | 19.19% | 39.08% |
| Operating Income | $-26.00M | $172.00M | $246.00M | $181.00M | $662.00M |
| Operating Income Ratio | -1.23% | 7.85% | 10.29% | 8.57% | 28.46% |
| Total Other Income Expenses Net | $2.00M | $-12.00M | $-127.00M | $-57.00M | $-116.00M |
| Income Before Tax | $-24.00M | $160.00M | $206.00M | $135.00M | $-503.00M |
| Income Before Tax Ratio | -1.14% | 7.30% | 8.62% | 6.40% | -21.63% |
| Income Tax Expense | $-223.00M | $-8.00M | $25.00M | $-38.00M | $-12.00M |
| Net Income | $169.00M | $178.00M | $181.00M | $173.00M | $-491.00M |
| Net Income Ratio | 8.00% | 8.12% | 7.57% | 8.20% | -21.11% |
| EPS | $3.45 | $3.36 | $3.29 | $2.88 | $-8.05 |
| EPS Diluted | $3.38 | $3.36 | $3.23 | $2.84 | $-8.05 |
| Weighted Average Shares Outstanding | 49.00M | 53.00M | 55.00M | 60.00M | 61.00M |
| Weighted Average Shares Outstanding Diluted | 50.00M | 54.00M | 56.00M | 61.00M | 61.00M |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $405.00M | $522.00M | $544.00M | $575.00M | $848.00M | $518.00M | $546.00M | $603.00M | $525.00M | $631.00M | $644.00M | $604.00M | $512.00M | $591.00M | $637.00M | $598.00M | $552.00M | $609.00M | $574.00M | $610.00M |
| Cost of Revenue | $294.00M | $368.00M | $418.00M | $435.00M | $750.00M | $389.00M | $368.00M | $406.00M | $360.00M | $422.00M | $404.00M | $384.00M | $351.00M | $401.00M | $439.00M | $407.00M | $374.00M | $448.00M | $378.00M | $413.00M |
| Gross Profit | $111.00M | $154.00M | $126.00M | $140.00M | $98.00M | $129.00M | $178.00M | $197.00M | $165.00M | $209.00M | $240.00M | $220.00M | $161.00M | $190.00M | $198.00M | $191.00M | $178.00M | $161.00M | $196.00M | $197.00M |
| Gross Profit Ratio | 27.41% | 29.50% | 23.20% | 24.30% | 11.60% | 24.90% | 32.60% | 32.70% | 31.40% | 33.10% | 37.30% | 36.40% | 31.40% | 32.10% | 31.10% | 31.90% | 32.20% | 26.44% | 34.15% | 32.30% |
| Research and Development Expenses | $13.00M | $13.00M | $15.00M | $14.00M | $12.00M | $14.00M | $12.00M | $12.00M | $13.00M | $14.00M | $14.00M | $13.00M | $13.00M | $13.00M | $15.00M | $14.00M | $15.00M | $16.00M | $14.00M | $18.00M |
| General and Administrative Expenses | $- | $101.00M | $114.00M | $106.00M | $83.00M | $107.00M | $82.00M | $79.00M | $- | $92.00M | $- | $- | $- | $84.00M | $- | $- | $106.00M | $318.00M | $- | $- |
| Selling and Marketing Expenses | $- | $1.00M | $-45.00M | $-19.00M | $- | $2.00M | $2.00M | $- | $- | $2.00M | $- | $- | $- | $1.00M | $- | $- | $- | $-209.00M | $- | $- |
| Selling General and Administrative Expenses | $78.00M | $105.00M | $69.00M | $87.00M | $83.00M | $109.00M | $84.00M | $79.00M | $93.00M | $94.00M | $127.00M | $90.00M | $82.00M | $85.00M | $98.00M | $84.00M | $106.00M | $109.00M | $113.00M | $103.00M |
| Other Expenses | $199.00M | $- | $131.00M | $-2.00M | $-2.00M | $-3.00M | $-2.00M | $23.00M | $23.00M | $23.00M | $-1.00M | $24.00M | $24.00M | $-1.00M | $-1.00M | $22.00M | $21.00M | $1.00M | $21.00M | $14.00M |
| Operating Expenses | $290.00M | $114.00M | $84.00M | $101.00M | $95.00M | $146.00M | $120.00M | $114.00M | $129.00M | $131.00M | $164.00M | $127.00M | $119.00M | $122.00M | $137.00M | $120.00M | $142.00M | $146.00M | $148.00M | $142.00M |
| Cost and Expenses | $584.00M | $491.00M | $502.00M | $554.00M | $845.00M | $535.00M | $488.00M | $520.00M | $489.00M | $553.00M | $568.00M | $511.00M | $470.00M | $523.00M | $576.00M | $527.00M | $516.00M | $594.00M | $526.00M | $555.00M |
| Interest Income | $2.00M | $2.00M | $3.00M | $2.00M | $3.00M | $3.00M | $2.00M | $3.00M | $4.00M | $4.00M | $- | $- | $- | $1.00M | $- | $- | $- | $- | $- | $- |
| Interest Expense | $18.00M | $- | $14.00M | $13.00M | $13.00M | $28.00M | $3.00M | $15.00M | $14.00M | $15.00M | $14.00M | $16.00M | $16.00M | $19.00M | $17.00M | $17.00M | $16.00M | $26.00M | $19.00M | $117.00M |
| Depreciation and Amortization | $26.00M | $53.00M | $104.00M | $86.00M | $81.00M | $87.00M | $82.00M | $64.00M | $67.00M | $66.00M | $107.00M | $73.00M | $63.00M | $75.00M | $89.00M | $62.00M | $62.00M | $63.00M | $62.00M | $61.00M |
| EBITDA | $-140.00M | $83.00M | $48.00M | $119.00M | $100.00M | $38.00M | $154.00M | $170.00M | $132.00M | $144.00M | $173.00M | $148.00M | $117.00M | $124.00M | $169.00M | $131.00M | $93.00M | $78.00M | $122.00M | $-494.00M |
| EBITDA Ratio | -34.57% | 15.90% | 26.84% | 21.74% | -2.12% | 8.88% | 21.98% | 23.71% | 18.10% | 21.87% | 21.27% | 24.34% | 19.92% | 22.34% | 19.47% | 21.91% | 15.22% | 12.81% | 19.16% | 105.90% |
| Operating Income | $-166.00M | $31.00M | $42.00M | $39.00M | $-18.00M | $-10.00M | $62.00M | $83.00M | $37.00M | $79.00M | $77.00M | $93.00M | $42.00M | $70.00M | $62.00M | $71.00M | $41.00M | $15.00M | $48.00M | $-468.00M |
| Operating Income Ratio | -40.99% | 5.94% | 7.72% | 6.78% | -2.12% | -1.93% | 11.36% | 13.76% | 7.05% | 12.52% | 11.96% | 15.40% | 8.20% | 11.84% | 9.73% | 11.87% | 7.43% | 2.46% | 8.36% | -76.72% |
| Total Other Income Expenses Net | $-43.00M | $-6.00M | $-9.00M | $-4.00M | $22.00M | $-27.00M | $-5.00M | $8.00M | $13.00M | $-60.00M | $-25.00M | $-35.00M | $-5.00M | $-40.00M | $1.00M | $-28.00M | $20.00M | $-6.00M | $14.00M | $-117.00M |
| Income Before Tax | $-209.00M | $25.00M | $-70.00M | $17.00M | $4.00M | $-38.00M | $57.00M | $91.00M | $50.00M | $61.00M | $52.00M | $58.00M | $37.00M | $31.00M | $63.00M | $43.00M | $61.00M | $9.00M | $62.00M | $-585.00M |
| Income Before Tax Ratio | -51.60% | 4.79% | -12.87% | 2.96% | 0.47% | -7.34% | 10.44% | 15.09% | 9.52% | 9.67% | 8.07% | 9.60% | 7.23% | 5.25% | 9.89% | 7.19% | 11.05% | 1.48% | 10.80% | -95.90% |
| Income Tax Expense | $-44.00M | $6.00M | $-101.00M | $-104.00M | $-24.00M | $-30.00M | $15.00M | $-1.00M | $8.00M | $1.00M | $1.00M | $20.00M | $5.00M | $-2.00M | $-24.00M | $19.00M | $47.00M | $9.00M | $12.00M | $-10.00M |
| Net Income | $-165.00M | $16.00M | $14.00M | $120.00M | $26.00M | $-4.00M | $50.00M | $91.00M | $40.00M | $57.00M | $36.00M | $38.00M | $48.00M | $43.00M | $80.00M | $41.00M | $56.00M | $5.00M | $37.00M | $-582.00M |
| Net Income Ratio | -40.74% | 3.07% | 2.57% | 20.87% | 3.07% | -0.77% | 9.16% | 15.09% | 7.62% | 9.03% | 5.59% | 6.29% | 9.38% | 7.28% | 12.56% | 6.86% | 10.14% | 0.82% | 6.45% | -95.41% |
| EPS | $-3.50 | $0.34 | $0.28 | $2.40 | $0.57 | $-0.08 | $0.98 | $1.69 | $0.76 | $1.06 | $0.66 | $0.68 | $0.84 | $0.75 | $1.32 | $0.68 | $0.92 | $0.08 | $0.61 | $-9.63 |
| EPS Diluted | $-3.50 | $0.33 | $0.27 | $2.35 | $0.57 | $-0.08 | $0.96 | $1.65 | $0.75 | $1.04 | $0.65 | $0.67 | $0.83 | $0.72 | $1.29 | $0.67 | $0.91 | $0.07 | $0.61 | $-9.54 |
| Weighted Average Shares Outstanding | 47.18M | 47.00M | 50.00M | 50.00M | 51.00M | 51.00M | 52.00M | 54.00M | 54.00M | 54.00M | 54.00M | 56.00M | 56.92M | 57.00M | 60.73M | 61.00M | 60.67M | 60.95M | 60.47M | 60.46M |
| Weighted Average Shares Outstanding Diluted | 47.18M | 49.00M | 51.00M | 51.00M | 51.00M | 51.00M | 53.00M | 55.00M | 55.00M | 55.00M | 55.00M | 57.00M | 58.00M | 61.00M | 62.00M | 62.00M | 61.00M | 61.00M | 61.00M | 61.00M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | September 30, 2024 | September 30, 2023 | September 30, 2022 | September 30, 2021 | September 30, 2020 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $300.00M | $417.00M | $646.00M | $210.00M | $454.00M |
| Short Term Investments | $- | $77.00M | $61.00M | $37.00M | $30.00M |
| Cash and Short Term Investments | $300.00M | $417.00M | $646.00M | $210.00M | $454.00M |
| Net Receivables | $227.00M | $338.00M | $382.00M | $350.00M | $422.00M |
| Inventory | $545.00M | $626.00M | $629.00M | $473.00M | $529.00M |
| Other Current Assets | $123.00M | $125.00M | $111.00M | $684.00M | $165.00M |
| Total Current Assets | $1.20B | $1.51B | $1.77B | $1.72B | $1.55B |
| Property Plant Equipment Net | $1.42B | $1.50B | $1.45B | $1.55B | $1.70B |
| Goodwill | $1.38B | $1.36B | $1.31B | $1.43B | $1.76B |
| Intangible Assets | $757.00M | $886.00M | $963.00M | $1.10B | $1.01B |
| Goodwill and Intangible Assets | $2.14B | $2.25B | $2.27B | $2.53B | $2.77B |
| Long Term Investments | $3.00M | $435.00M | $3.00M | $4.00M | $5.00M |
| Tax Assets | $- | $22.00M | $20.00M | $30.00M | $26.00M |
| Other Non-Current Assets | $892.00M | $233.00M | $702.00M | $781.00M | $826.00M |
| Total Non-Current Assets | $4.45B | $4.43B | $4.45B | $4.89B | $5.33B |
| Other Assets | $- | $- | $- | $- | $- |
| Total Assets | $5.64B | $5.94B | $6.21B | $6.61B | $6.88B |
| Account Payables | $214.00M | $210.00M | $265.00M | $236.00M | $211.00M |
| Short Term Debt | $20.00M | $38.00M | $19.00M | $397.00M | $302.00M |
| Tax Payables | $- | $- | $-47.00M | $- | $- |
| Deferred Revenue | $- | $- | $- | $251.00M | $- |
| Other Current Liabilities | $256.00M | $208.00M | $316.00M | $301.00M | $300.00M |
| Total Current Liabilities | $490.00M | $456.00M | $553.00M | $934.00M | $813.00M |
| Long Term Debt | $1.45B | $1.42B | $1.36B | $1.71B | $1.69B |
| Deferred Revenue Non-Current | $- | $- | $- | $634.00M | $670.00M |
| Deferred Tax Liabilities Non-Current | $- | $148.00M | $176.00M | $237.00M | $229.00M |
| Other Non-Current Liabilities | $839.00M | $818.00M | $900.00M | $983.00M | $1.11B |
| Total Non-Current Liabilities | $2.29B | $2.39B | $2.44B | $2.93B | $3.03B |
| Other Liabilities | $- | $- | $- | $- | $- |
| Total Liabilities | $2.78B | $2.84B | $2.99B | $3.86B | $3.84B |
| Preferred Stock | $- | $- | $- | $- | $- |
| Common Stock | $1.00M | $1.00M | $1.00M | $1.00M | $1.00M |
| Retained Earnings | $3.31B | $3.60B | $3.65B | $2.80B | $2.65B |
| Accumulated Other Comprehensive Income Loss | $-448.00M | $-503.00M | $-569.00M | $-372.00M | $-383.00M |
| Other Total Stockholders Equity | $- | $4.00M | $135.00M | $327.00M | $769.00M |
| Total Stockholders Equity | $2.87B | $3.10B | $3.22B | $2.75B | $3.04B |
| Total Equity | $2.87B | $3.10B | $3.22B | $2.75B | $3.04B |
| Total Liabilities and Stockholders Equity | $5.64B | $5.94B | $6.21B | $6.61B | $6.88B |
| Minority Interest | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $5.64B | $5.94B | $6.21B | $6.61B | $6.88B |
| Total Investments | $3.00M | $3.00M | $3.00M | $4.00M | $5.00M |
| Total Debt | $1.47B | $1.46B | $1.38B | $2.10B | $2.00B |
| Net Debt | $1.17B | $1.04B | $737.00M | $1.89B | $1.55B |
Balance Sheet Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $219.00M | $300.00M | $399.00M | $439.00M | $440.00M | $417.00M | $349.00M | $399.00M | $532.00M | $646.00M | $629.00M | $964.00M | $194.00M | $210.00M | $262.00M | $373.00M | $335.00M | $454.00M | $416.00M | $353.00M |
| Short Term Investments | $- | $- | $76.00M | $77.00M | $77.00M | $77.00M | $71.00M | $61.00M | $61.00M | $61.00M | $61.00M | $36.00M | $36.00M | $37.00M | $27.00M | $- | $- | $- | $- | $- |
| Cash and Short Term Investments | $219.00M | $300.00M | $475.00M | $516.00M | $440.00M | $417.00M | $349.00M | $399.00M | $532.00M | $646.00M | $629.00M | $964.00M | $194.00M | $210.00M | $262.00M | $373.00M | $335.00M | $454.00M | $416.00M | $353.00M |
| Net Receivables | $163.00M | $243.00M | $224.00M | $260.00M | $194.00M | $338.00M | $345.00M | $395.00M | $351.00M | $382.00M | $488.00M | $407.00M | $340.00M | $350.00M | $384.00M | $447.00M | $409.00M | $471.00M | $455.00M | $498.00M |
| Inventory | $528.00M | $545.00M | $532.00M | $550.00M | $588.00M | $626.00M | $712.00M | $730.00M | $724.00M | $629.00M | $609.00M | $573.00M | $530.00M | $473.00M | $517.00M | $512.00M | $537.00M | $529.00M | $617.00M | $611.00M |
| Other Current Assets | $159.00M | $107.00M | $230.00M | $178.00M | $143.00M | $125.00M | $120.00M | $107.00M | $117.00M | $111.00M | $91.00M | $81.00M | $670.00M | $684.00M | $72.00M | $86.00M | $100.00M | $93.00M | $182.00M | $183.00M |
| Total Current Assets | $1.07B | $1.20B | $1.39B | $1.43B | $1.36B | $1.51B | $1.53B | $1.63B | $1.72B | $1.77B | $1.82B | $2.02B | $1.73B | $1.72B | $1.24B | $1.42B | $1.38B | $1.55B | $1.67B | $1.65B |
| Property Plant Equipment Net | $1.33B | $1.42B | $1.41B | $1.46B | $1.49B | $1.50B | $1.48B | $1.48B | $1.45B | $1.45B | $1.46B | $1.50B | $1.52B | $1.55B | $1.66B | $1.66B | $1.70B | $1.70B | $1.69B | $1.71B |
| Goodwill | $1.33B | $1.38B | $1.35B | $1.38B | $1.40B | $1.36B | $1.38B | $1.39B | $1.37B | $1.31B | $1.36B | $1.40B | $1.41B | $1.43B | $1.90B | $1.76B | $1.79B | $1.76B | $1.73B | $1.72B |
| Intangible Assets | $588.00M | $751.00M | $761.00M | $851.00M | $875.00M | $886.00M | $916.00M | $940.00M | $959.00M | $963.00M | $1.00B | $1.04B | $1.07B | $1.10B | $1.13B | $971.00M | $1.00B | $1.01B | $1.03B | $1.04B |
| Goodwill and Intangible Assets | $1.92B | $2.14B | $2.11B | $2.23B | $2.27B | $2.25B | $2.30B | $2.33B | $2.33B | $2.27B | $2.36B | $2.44B | $2.48B | $2.53B | $3.03B | $2.73B | $2.79B | $2.77B | $2.76B | $2.77B |
| Long Term Investments | $- | $3.00M | $423.00M | $439.00M | $124.00M | $127.00M | $129.00M | $498.00M | $495.00M | $3.00M | $9.00M | $533.00M | $390.00M | $4.00M | $136.00M | $128.00M | $130.00M | $5.00M | $138.00M | $277.00M |
| Tax Assets | $241.00M | $210.00M | $160.00M | $150.00M | $45.00M | $22.00M | $20.00M | $20.00M | $20.00M | $20.00M | $30.00M | $30.00M | $30.00M | $30.00M | $26.00M | $26.00M | $26.00M | $26.00M | $24.00M | $24.00M |
| Other Non-Current Assets | $670.00M | $682.00M | $256.00M | $245.00M | $571.00M | $541.00M | $575.00M | $234.00M | $239.00M | $702.00M | $735.00M | $252.00M | $398.00M | $781.00M | $677.00M | $697.00M | $713.00M | $826.00M | $700.00M | $547.00M |
| Total Non-Current Assets | $4.16B | $4.45B | $4.36B | $4.52B | $4.50B | $4.43B | $4.50B | $4.55B | $4.54B | $4.45B | $4.59B | $4.75B | $4.82B | $4.89B | $5.53B | $5.25B | $5.36B | $5.33B | $5.32B | $5.32B |
| Other Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Assets | $5.23B | $5.64B | $5.75B | $5.95B | $5.87B | $5.94B | $6.03B | $6.18B | $6.26B | $6.21B | $6.41B | $6.78B | $6.55B | $6.61B | $6.77B | $6.66B | $6.74B | $6.88B | $6.99B | $6.97B |
| Account Payables | $184.00M | $214.00M | $198.00M | $207.00M | $202.00M | $210.00M | $210.00M | $246.00M | $246.00M | $265.00M | $241.00M | $248.00M | $236.00M | $236.00M | $236.00M | $217.00M | $217.00M | $211.00M | $225.00M | $255.00M |
| Short Term Debt | $20.00M | $20.00M | $42.00M | $42.00M | $44.00M | $38.00M | $42.00M | $40.00M | $36.00M | $19.00M | $36.00M | $42.00M | $433.00M | $397.00M | $149.00M | $134.00M | $139.00M | $325.00M | $492.00M | $517.00M |
| Tax Payables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-47.00M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Revenue | $- | $- | $- | $- | $-202.00M | $- | $- | $- | $20.00M | $- | $-18.00M | $- | $214.00M | $251.00M | $- | $- | $26.00M | $26.00M | $238.00M | $218.00M |
| Other Current Liabilities | $221.00M | $256.00M | $224.00M | $204.00M | $168.00M | $208.00M | $180.00M | $186.00M | $182.00M | $316.00M | $273.00M | $520.00M | $239.00M | $301.00M | $217.00M | $218.00M | $229.00M | $277.00M | $220.00M | $200.00M |
| Total Current Liabilities | $425.00M | $490.00M | $464.00M | $453.00M | $414.00M | $456.00M | $432.00M | $472.00M | $464.00M | $553.00M | $550.00M | $810.00M | $908.00M | $934.00M | $602.00M | $569.00M | $585.00M | $813.00M | $937.00M | $972.00M |
| Long Term Debt | $1.40B | $1.45B | $1.43B | $1.43B | $1.45B | $1.42B | $1.44B | $1.44B | $1.41B | $1.36B | $1.40B | $1.44B | $1.68B | $1.71B | $1.70B | $1.69B | $1.73B | $1.69B | $1.67B | $1.67B |
| Deferred Revenue Non-Current | $- | $- | $100.00M | $101.00M | $510.00M | $527.00M | $545.00M | $- | $176.00M | $- | $620.00M | $- | $617.00M | $634.00M | $659.00M | $641.00M | $655.00M | $670.00M | $677.00M | $681.00M |
| Deferred Tax Liabilities Non-Current | $28.00M | $- | $43.00M | $148.00M | $148.00M | $148.00M | $176.00M | $175.00M | $176.00M | $176.00M | $218.00M | $218.00M | $238.00M | $237.00M | $243.00M | $229.00M | $222.00M | $229.00M | $248.00M | $250.00M |
| Other Non-Current Liabilities | $790.00M | $839.00M | $848.00M | $784.00M | $803.00M | $818.00M | $835.00M | $833.00M | $890.00M | $900.00M | $976.00M | $933.00M | $956.00M | $983.00M | $1.02B | $1.06B | $1.09B | $1.11B | $1.11B | $1.10B |
| Total Non-Current Liabilities | $2.21B | $2.29B | $2.32B | $2.36B | $2.40B | $2.39B | $2.45B | $2.44B | $2.48B | $2.44B | $2.60B | $2.59B | $2.88B | $2.93B | $2.96B | $2.98B | $3.04B | $3.03B | $3.04B | $3.01B |
| Other Liabilities | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities | $2.64B | $2.78B | $2.78B | $2.81B | $2.81B | $2.84B | $2.88B | $2.92B | $2.94B | $2.99B | $3.15B | $3.40B | $3.79B | $3.86B | $3.56B | $3.55B | $3.62B | $3.84B | $3.97B | $3.98B |
| Preferred Stock | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $64.00M | $- | $- | $- | $- | $- | $- | $- |
| Common Stock | $- | $1.00M | $- | $6.00M | $1.00M | $1.00M | $- | $- | $134.00M | $1.00M | $133.00M | $177.00M | $328.00M | $1.00M | $1.00M | $1.00M | $1.00M | $1.00M | $1.00M | $1.00M |
| Retained Earnings | $- | $3.31B | $3.47B | $3.60B | $3.50B | $3.60B | $3.62B | $3.73B | $3.67B | $3.65B | $3.61B | $3.60B | $2.86B | $2.80B | $2.77B | $2.71B | $2.69B | $2.65B | $2.66B | $2.64B |
| Accumulated Other Comprehensive Income Loss | $- | $-448.00M | $-499.00M | $-476.00M | $-450.00M | $-503.00M | $-470.00M | $-467.00M | $-491.00M | $-569.00M | $-481.00M | $-392.00M | $-392.00M | $-372.00M | $-1.82B | $-1.77B | $-335.00M | $-383.00M | $-417.00M | $-424.00M |
| Other Total Stockholders Equity | $2.59B | $- | $- | $- | $- | $4.00M | $- | $- | $- | $135.00M | $- | $- | $- | $327.00M | $776.00M | $772.00M | $770.00M | $769.00M | $768.00M | $765.00M |
| Total Stockholders Equity | $2.59B | $2.87B | $2.97B | $3.13B | $3.05B | $3.10B | $3.15B | $3.27B | $3.32B | $3.22B | $3.27B | $3.38B | $2.76B | $2.75B | $3.20B | $3.11B | $3.12B | $3.04B | $3.01B | $2.98B |
| Total Equity | $2.59B | $2.87B | $2.97B | $3.13B | $3.05B | $3.10B | $3.15B | $3.27B | $3.32B | $3.22B | $3.27B | $3.38B | $2.76B | $2.75B | $3.20B | $3.11B | $3.12B | $3.04B | $3.01B | $2.98B |
| Total Liabilities and Stockholders Equity | $5.23B | $5.64B | $5.75B | $5.95B | $5.87B | $5.94B | $6.03B | $6.18B | $6.26B | $6.21B | $6.41B | $6.78B | $6.55B | $6.61B | $6.77B | $6.66B | $6.74B | $6.88B | $6.99B | $6.97B |
| Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $5.23B | $5.64B | $5.75B | $5.95B | $5.87B | $5.94B | $6.03B | $6.18B | $6.26B | $6.21B | $6.41B | $6.78B | $6.55B | $6.61B | $6.77B | $6.66B | $6.74B | $6.88B | $6.99B | $6.97B |
| Total Investments | $- | $3.00M | $499.00M | $516.00M | $528.00M | $127.00M | $129.00M | $559.00M | $556.00M | $3.00M | $9.00M | $569.00M | $390.00M | $4.00M | $136.00M | $128.00M | $130.00M | $5.00M | $138.00M | $277.00M |
| Total Debt | $1.42B | $1.47B | $1.45B | $1.45B | $1.47B | $1.46B | $1.46B | $1.46B | $1.43B | $1.38B | $1.42B | $1.46B | $2.10B | $2.10B | $1.82B | $1.80B | $1.84B | $2.00B | $2.14B | $2.16B |
| Net Debt | $1.20B | $1.17B | $1.05B | $1.01B | $1.03B | $1.04B | $1.11B | $1.06B | $897.00M | $737.00M | $791.00M | $495.00M | $1.90B | $1.89B | $1.56B | $1.43B | $1.51B | $1.55B | $1.73B | $1.81B |
Annual Cash Flow
| Breakdown | September 30, 2024 | September 30, 2023 | September 30, 2022 | September 30, 2021 | September 30, 2020 |
|---|---|---|---|---|---|
| Net Income | $169.00M | $178.00M | $927.00M | $220.00M | $-508.00M |
| Depreciation and Amortization | $274.00M | $243.00M | $241.00M | $244.00M | $247.00M |
| Deferred Income Tax | $-302.00M | $-32.00M | $-25.00M | $-26.00M | $-43.00M |
| Stock Based Compensation | $15.00M | $22.00M | $18.00M | $15.00M | $14.00M |
| Change in Working Capital | $227.00M | $-58.00M | $-247.00M | $80.00M | $19.00M |
| Accounts Receivables | $96.00M | $-23.00M | $-23.00M | $72.00M | $7.00M |
| Inventory | $79.00M | $-141.00M | $-141.00M | $41.00M | $65.00M |
| Accounts Payables | $- | $-112.00M | $34.00M | $3.00M | $-50.00M |
| Other Working Capital | $52.00M | $218.00M | $-117.00M | $-36.00M | $-3.00M |
| Other Non Cash Items | $79.00M | $-110.00M | $-1.13B | $27.00M | $474.00M |
| Net Cash Provided by Operating Activities | $462.00M | $243.00M | $-213.00M | $560.00M | $203.00M |
| Investments in Property Plant and Equipment | $-137.00M | $-170.00M | $-113.00M | $-105.00M | $-138.00M |
| Acquisitions Net | $- | $11.00M | $51.00M | $-295.00M | $9.00M |
| Purchases of Investments | $-53.00M | $-47.00M | $-87.00M | $-149.00M | $-21.00M |
| Sales Maturities of Investments | $53.00M | $47.00M | $87.00M | $150.00M | $21.00M |
| Other Investing Activities | $35.00M | $50.00M | $1.62B | $18.00M | $137.00M |
| Net Cash Used for Investing Activities | $-102.00M | $-109.00M | $1.56B | $-381.00M | $8.00M |
| Debt Repayment | $-16.00M | $16.00M | $-615.00M | $107.00M | $93.00M |
| Common Stock Issued | $- | $- | $- | $- | $7.00M |
| Common Stock Repurchased | $-380.00M | $-300.00M | $-200.00M | $-450.00M | $-7.00M |
| Dividends Paid | $-78.00M | $-76.00M | $-70.00M | $-70.00M | $-66.00M |
| Other Financing Activities | $-5.00M | $-11.00M | $-11.00M | $-13.00M | $-18.00M |
| Net Cash Used Provided by Financing Activities | $-479.00M | $-371.00M | $-896.00M | $-426.00M | $9.00M |
| Effect of Forex Changes on Cash | $- | $8.00M | $-11.00M | $3.00M | $2.00M |
| Net Change in Cash | $-117.00M | $-229.00M | $436.00M | $-244.00M | $222.00M |
| Cash at End of Period | $300.00M | $417.00M | $646.00M | $210.00M | $454.00M |
| Cash at Beginning of Period | $417.00M | $646.00M | $210.00M | $454.00M | $232.00M |
| Operating Cash Flow | $462.00M | $243.00M | $-213.00M | $560.00M | $203.00M |
| Capital Expenditure | $-137.00M | $-170.00M | $-113.00M | $-105.00M | $-138.00M |
| Free Cash Flow | $325.00M | $73.00M | $-326.00M | $455.00M | $65.00M |
Cash Flow Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $-165.00M | $16.00M | $31.00M | $121.00M | $26.00M | $-4.00M | $50.00M | $91.00M | $42.00M | $57.00M | $36.00M | $786.00M | $48.00M | $43.00M | $87.00M | $41.00M | $56.00M | $5.00M | $37.00M | $-582.00M |
| Depreciation and Amortization | $51.00M | $57.00M | $104.00M | $86.00M | $77.00M | $62.00M | $62.00M | $60.00M | $59.00M | $60.00M | $61.00M | $61.00M | $60.00M | $64.00M | $65.00M | $62.00M | $62.00M | $63.00M | $62.00M | $61.00M |
| Deferred Income Tax | $-3.00M | $-165.00M | $-1.00M | $-106.00M | $-30.00M | $-44.00M | $-4.00M | $8.00M | $7.00M | $-20.00M | $-2.00M | $-6.00M | $3.00M | $-22.00M | $9.00M | $-7.00M | $-5.00M | $-13.00M | $-2.00M | $-16.00M |
| Stock Based Compensation | $4.00M | $3.00M | $3.00M | $6.00M | $1.00M | $5.00M | $5.00M | $5.00M | $7.00M | $4.00M | $5.00M | $5.00M | $4.00M | $3.00M | $4.00M | $4.00M | $4.00M | $3.00M | $3.00M | $4.00M |
| Change in Working Capital | $- | $157.00M | $-60.00M | $-37.00M | $167.00M | $108.00M | $46.00M | $-88.00M | $-123.00M | $68.00M | $-136.00M | $-107.00M | $-72.00M | $48.00M | $91.00M | $-48.00M | $17.00M | $121.00M | $62.00M | $-54.00M |
| Accounts Receivables | $- | $- | $- | $- | $- | $-23.00M | $- | $- | $- | $-23.00M | $- | $- | $- | $72.00M | $- | $- | $- | $7.00M | $19.00M | $-59.00M |
| Inventory | $- | $- | $- | $- | $- | $-141.00M | $- | $- | $- | $-141.00M | $- | $- | $- | $41.00M | $- | $4.00M | $- | $65.00M | $15.00M | $4.00M |
| Accounts Payables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-685.00M | $- | $- |
| Other Working Capital | $-109.00M | $157.00M | $-60.00M | $-37.00M | $167.00M | $272.00M | $46.00M | $-88.00M | $-123.00M | $232.00M | $-135.00M | $-108.00M | $-72.00M | $48.00M | $91.00M | $-52.00M | $17.00M | $734.00M | $62.00M | $-58.00M |
| Other Non Cash Items | $83.00M | $12.00M | $261.00M | $162.00M | $-54.00M | $-6.00M | $-19.00M | $-33.00M | $-55.00M | $-94.00M | $-27.00M | $-787.00M | $-37.00M | $25.00M | $-34.00M | $33.00M | $-42.00M | $-31.00M | $-41.00M | $572.00M |
| Net Cash Provided by Operating Activities | $-30.00M | $80.00M | $127.00M | $54.00M | $187.00M | $122.00M | $140.00M | $43.00M | $-63.00M | $75.00M | $-246.00M | $-48.00M | $6.00M | $161.00M | $222.00M | $85.00M | $92.00M | $148.00M | $121.00M | $-15.00M |
| Investments in Property Plant and Equipment | $-23.00M | $-38.00M | $-29.00M | $-34.00M | $-36.00M | $-69.00M | $-44.00M | $-35.00M | $-23.00M | $-46.00M | $-29.00M | $-22.00M | $-15.00M | $-31.00M | $-23.00M | $-25.00M | $-30.00M | $-44.00M | $-28.00M | $-37.00M |
| Acquisitions Net | $- | $- | $- | $- | $- | $9.00M | $3.00M | $- | $- | $- | $40.00M | $10.00M | $1.00M | $-1.00M | $-308.00M | $-6.00M | $14.00M | $9.00M | $- | $-1.00M |
| Purchases of Investments | $-5.00M | $-14.00M | $-19.00M | $-11.00M | $-9.00M | $-11.00M | $-21.00M | $-15.00M | $- | $-12.00M | $-29.00M | $-42.00M | $-4.00M | $-93.00M | $-9.00M | $-5.00M | $-42.00M | $-5.00M | $-6.00M | $-6.00M |
| Sales Maturities of Investments | $5.00M | $14.00M | $42.00M | $32.00M | $9.00M | $11.00M | $21.00M | $15.00M | $- | $12.00M | $29.00M | $42.00M | $4.00M | $93.00M | $9.00M | $5.00M | $42.00M | $5.00M | $6.00M | $6.00M |
| Other Investing Activities | $5.00M | $28.00M | $-10.00M | $31.00M | $10.00M | $9.00M | $29.00M | $17.00M | $-4.00M | $12.00M | $-28.00M | $1.64B | $7.00M | $3.00M | $7.00M | $9.00M | $9.00M | $107.00M | $12.00M | $8.00M |
| Net Cash Used for Investing Activities | $-18.00M | $-10.00M | $-16.00M | $18.00M | $-26.00M | $-51.00M | $-12.00M | $-18.00M | $-27.00M | $-34.00M | $-18.00M | $1.62B | $-8.00M | $-29.00M | $-324.00M | $-22.00M | $-7.00M | $72.00M | $-16.00M | $-30.00M |
| Debt Repayment | $- | $- | $- | $- | $-16.00M | $16.00M | $- | $- | $- | $- | $- | $-626.00M | $- | $292.00M | $10.00M | $-8.00M | $-187.00M | $-166.00M | $- | $- |
| Common Stock Issued | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $719.00M | $- | $- | $- | $- | $- | $- |
| Common Stock Repurchased | $- | $-150.00M | $-130.00M | $-1.00M | $-100.00M | $-1.00M | $-158.00M | $-142.00M | $-9.00M | $- | $-45.00M | $-155.00M | $-5.00M | $-450.00M | $-1.00M | $-2.00M | $-3.00M | $-1.00M | $- | $-1.00M |
| Dividends Paid | $-19.00M | $-19.00M | $-20.00M | $-19.00M | $-20.00M | $-20.00M | $-20.00M | $-18.00M | $-18.00M | $-18.00M | $-18.00M | $-17.00M | $-17.00M | $-18.00M | $-18.00M | $-16.00M | $-17.00M | $-16.00M | $-17.00M | $-17.00M |
| Other Financing Activities | $-3.00M | $- | $-1.00M | $-1.00M | $-3.00M | $-1.00M | $- | $-1.00M | $-9.00M | $-2.00M | $-3.00M | $-1.00M | $11.00M | $-7.00M | $-1.00M | $- | $- | $- | $-25.00M | $259.00M |
| Net Cash Used Provided by Financing Activities | $-22.00M | $-169.00M | $-151.00M | $-20.00M | $-139.00M | $-5.00M | $-178.00M | $-161.00M | $-27.00M | $-20.00M | $-66.00M | $-799.00M | $-11.00M | $-183.00M | $-9.00M | $-26.00M | $-207.00M | $-183.00M | $-42.00M | $241.00M |
| Effect of Forex Changes on Cash | $-1.00M | $- | $- | $1.00M | $1.00M | $2.00M | $1.00M | $3.00M | $3.00M | $-4.00M | $-5.00M | $1.00M | $-3.00M | $-1.00M | $- | $1.00M | $3.00M | $1.00M | $- | $- |
| Net Change in Cash | $-81.00M | $-99.00M | $-40.00M | $-1.00M | $23.00M | $68.00M | $-50.00M | $-133.00M | $-114.00M | $17.00M | $-335.00M | $770.00M | $-16.00M | $-52.00M | $-111.00M | $38.00M | $-119.00M | $38.00M | $63.00M | $196.00M |
| Cash at End of Period | $219.00M | $300.00M | $399.00M | $439.00M | $440.00M | $417.00M | $349.00M | $399.00M | $532.00M | $646.00M | $629.00M | $964.00M | $194.00M | $210.00M | $262.00M | $373.00M | $335.00M | $454.00M | $416.00M | $353.00M |
| Cash at Beginning of Period | $300.00M | $399.00M | $439.00M | $440.00M | $417.00M | $349.00M | $399.00M | $532.00M | $646.00M | $629.00M | $964.00M | $194.00M | $210.00M | $262.00M | $373.00M | $335.00M | $454.00M | $416.00M | $353.00M | $157.00M |
| Operating Cash Flow | $-30.00M | $80.00M | $127.00M | $54.00M | $187.00M | $122.00M | $140.00M | $43.00M | $-63.00M | $75.00M | $-246.00M | $-48.00M | $6.00M | $161.00M | $222.00M | $85.00M | $92.00M | $148.00M | $121.00M | $-15.00M |
| Capital Expenditure | $-23.00M | $-38.00M | $-29.00M | $-34.00M | $-36.00M | $-69.00M | $-44.00M | $-35.00M | $-23.00M | $-46.00M | $-29.00M | $-22.00M | $-15.00M | $-31.00M | $-23.00M | $-25.00M | $-30.00M | $-44.00M | $-28.00M | $-37.00M |
| Free Cash Flow | $-53.00M | $29.00M | $98.00M | $20.00M | $151.00M | $53.00M | $96.00M | $8.00M | $-86.00M | $29.00M | $-275.00M | $-70.00M | $-9.00M | $130.00M | $199.00M | $60.00M | $62.00M | $104.00M | $93.00M | $-52.00M |
Ashland Dividends
Explore Ashland's dividend history, including dividend yield, payout ratio, and historical payments.
Dividend Yield
1.83%
Dividend Payout Ratio
46.15%
Dividend Paid & Capex Coverage Ratio
2.15x
Ashland Dividend History
| Dividend | Adjusted Dividend | Date | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|
| $0.405 | $0.405 | February 28, 2025 | March 01, 2025 | March 15, 2025 | January 20, 2025 |
| $0.405 | $0.405 | November 29, 2024 | December 01, 2024 | December 15, 2024 | November 14, 2024 |
| $0.405 | $0.405 | August 30, 2024 | September 01, 2024 | September 15, 2024 | August 09, 2024 |
| $0.405 | $0.405 | May 31, 2024 | June 01, 2024 | June 15, 2024 | May 07, 2024 |
| $0.385 | $0.385 | February 29, 2024 | March 01, 2024 | March 15, 2024 | January 22, 2024 |
| $0.385 | $0.385 | November 30, 2023 | December 01, 2023 | December 15, 2023 | November 13, 2023 |
| $0.385 | $0.385 | August 31, 2023 | September 01, 2023 | September 15, 2023 | August 14, 2023 |
| $0.385 | $0.385 | May 31, 2023 | June 01, 2023 | June 15, 2023 | May 11, 2023 |
| $0.335 | $0.335 | February 28, 2023 | March 01, 2023 | March 15, 2023 | January 23, 2023 |
| $0.335 | $0.335 | November 30, 2022 | December 01, 2022 | December 15, 2022 | November 18, 2022 |
| $0.335 | $0.335 | August 31, 2022 | September 01, 2022 | September 15, 2022 | August 05, 2022 |
| $0.335 | $0.335 | May 31, 2022 | June 01, 2022 | June 15, 2022 | May 24, 2022 |
| $0.3 | $0.3 | February 28, 2022 | March 01, 2022 | March 15, 2022 | January 25, 2022 |
| $0.3 | $0.3 | November 30, 2021 | December 01, 2021 | December 15, 2021 | November 22, 2021 |
| $0.3 | $0.3 | August 31, 2021 | September 01, 2021 | September 15, 2021 | August 05, 2021 |
| $0.3 | $0.3 | May 28, 2021 | June 01, 2021 | June 15, 2021 | May 20, 2021 |
| $0.275 | $0.275 | February 25, 2021 | February 26, 2021 | March 15, 2021 | January 29, 2021 |
| $0.275 | $0.275 | November 30, 2020 | December 01, 2020 | December 15, 2020 | November 18, 2020 |
| $0.275 | $0.275 | August 31, 2020 | September 01, 2020 | September 15, 2020 | August 12, 2020 |
| $0.275 | $0.275 | May 29, 2020 | June 01, 2020 | June 15, 2020 | May 20, 2020 |
Ashland News
Read the latest news about Ashland, including recent articles, headlines, and updates.
Ashland Presents Attractive Upside Emerging From The Downcycle
Ashland is generating attractive free cash flow and is well-positioned to achieve its 2027 target of $600 million EBITDA and 50% FCF conversion rate. Despite the stock selling off over the last 8 months, Ashland's strategic acquisitions and divestitures have strengthened its market position, with a focus on high-margin, patent-protected products. Ashland's strong balance sheet, low leverage, and fixed-rate debt provide stability and flexibility to navigate the current downcycle in the specialty chemicals sector.
TScan Therapeutics: Finding Their Footing After An Eventful ASH Meeting
TScan Therapeutics is developing engineered T cell receptor therapies, with TSC-101 targeting HA-2 for acute leukemia, showing promising phase 1 results but potential GvHD risks. TCRX's financials are strong, with $133.1 million in cash and equivalents, funding operations into Q4 2026, despite high clinical development costs. The market undervalues TCRX stock, trading at less than half its Q3 assets, presenting an opportunity amid current biotech pessimism.
Ashland Inc. (ASH) Q1 2025 Earnings Call Transcript
Ashland Inc. (NYSE:ASH ) Q1 2025 Earnings Conference Call January 29, 2025 9:00 AM ET Company Participants William Whitaker - VP, Finance and Director, IR Guillermo Novo - Chair and CEO Kevin Willis - CFO Alessandra Faccin - SVP and GM, Life Sciences and Intermediates Jim Minicucci - SVP and GM, Personal Care Dago Caceres - SVP and GM, Specialty Additives Conference Call Participants Michael Sison - Wells Fargo Chris Parkinson - Wolfe Research John Roberts - Mizuho David Begleiter - Deutsche Bank Jeff Zekauskas - JPMorgan Mike Harrison - Seaport Research Partners Bhavesh Lodaya - BMO Capital Markets Josh Spector - UBS Operator Good day and thank you for standing by. Welcome to the Ashland Inc. First Quarter 2025 Earnings Conference Call.
Here's What Key Metrics Tell Us About Ashland (ASH) Q1 Earnings
Although the revenue and EPS for Ashland (ASH) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Ashland reports financial results for first quarter fiscal 20251, reiterates outlook for full-year fiscal 2025
WILMINGTON, Del., Jan. 28, 2025 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE: ASH) today announced financial results1 for the first quarter of fiscal year 2025, which ended December 31, 2024, and issued its full-year fiscal 2025 outlook. Ashland, a global additives and specialty ingredients company, holds leadership positions in high-quality, consumer-focused markets including pharmaceuticals, personal care and architectural coatings.
Stay Ahead of the Game With Ashland (ASH) Q1 Earnings: Wall Street's Insights on Key Metrics
Beyond analysts' top -and-bottom-line estimates for Ashland (ASH), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2024.
Forget The S&P 500 - 3 Small Dividend Stocks At Big Discounts
President Trump inherits a historically expensive stock market, with the Shiller P/E ratio indicating potentially subdued long-term returns for the S&P 500. Despite high valuations, opportunities exist, especially in smaller and mid-cap stocks, which are undervalued compared to large-cap stocks. The market's top-heavy nature, driven by FANG+ stocks, presents a risk/reward shift, making smaller companies more attractive.
Ashland board authorizes quarterly dividend
WILMINGTON, Del., Jan. 20, 2025 (GLOBE NEWSWIRE) -- The board of directors of Ashland Inc. (NYSE: ASH) has declared a quarterly cash dividend of $0.405 cents per share on the company's common stock. The dividend is payable on March 15, 2025, to stockholders of record at the close of business on March 1, 2025.
Ashland sets date for first-quarter fiscal 2025 earnings release and conference call webcast
WILMINGTON, Del., Jan. 14, 2025 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE: ASH) today announced plans to issue its first-quarter fiscal 2025 earnings release at approximately 5 p.m. ET on Tuesday, January 28, 2025. The company's live webcast with securities analysts will include an executive summary and detailed remarks. The live webcast will take place at 9 a.m. ET on Wednesday, January 29. Simultaneously, the company will post a slide presentation in the Investor Relations section of its website at http://investor.ashland.com.
Hematology Oncology of Indiana Physician Research Presented at 66th ASH Annual Meeting
INDIANAPOLIS, IN., Dec. 30, 2024 (GLOBE NEWSWIRE) -- Board-certified medical oncologists, M. Sarfraz Nawaz, MD and Ruemu E. Birhiray, MD from community oncology practice Hematology Oncology of Indiana (HOI), a partner practice of American Oncology Network (AON) (OTCQX: AONC), presented clinically meaningful and socially impactful research findings at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, held Dec. 7-10 in San Diego.
Ashland signs definitive agreement to sell Avoca business to Mane
Wilmington, Del., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE: ASH) announced today that it has signed a definitive agreement to sell its Avoca business to Mane. The transaction is expected to close in the calendar first quarter 2025, subject to the satisfaction of customary closing conditions.
Ashland price target lowered to $85 from $100 at Evercore ISI
Evercore ISI analyst Eric Boyes lowered the firm's price target on Ashland to $85 from $100 and keeps an In Line rating on the shares as a new analyst took over coverage of the stock and 10 other chemical names. Dissonance between sputtering industrial demand into year-end and prospects for a "less bad" 2025 has "muddled the forward outlook for chemicals investors" and the firm's sense is further EBITDA and EPS cuts coming to Q1 and FY25 "are needed to clear the deck," the analyst says. However, Evercore suspects the stocks "move sharply higher with signs of improving demand, so begin to position accordingly," the analyst added.
Ashland: A Stable Stock Trading At 50% Discount To Its Intrinsic Value
Ashland Inc. (NYSE: ASH) offers a promising upside of 58.3% with a target price of $125.72, driven by its strong financial fundamentals and growth potential in biotechnology. The company is well-diversified, primarily serving the pharmaceutical and cosmetic industries, which account for over two-thirds of its revenue. Despite a modest 2% dividend yield, Ashland consistently pays dividends and has a history of share buybacks, signaling shareholder commitment.
Live from ASH 2024 | Oral Report Features Encouraging Data of Ascentage Pharma's Bcl-2 Inhibitor Lisaftoclax in R/R MM, Including a Median PFS Over 9 Months
ROCKVILLE, Md. and SUZHOU, China , Dec. 10, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily for malignancies, today announced that it has released the latest clinical data of its novel Bcl-2 selective inhibitor, lisaftoclax (APG-2575), in patients with relapsed/refractory (R/R) multiple myeloma (MM) or immunoglobulin light-chain (AL) amyloidosis, in an Oral Report at the 66th American Society of Hematology (ASH) Annual Meeting, taking place in San Diego, CA, the United States.
Live from ASH 2024 | Ascentage Pharma Releases Updated Data of Bcl-2 Inhibitor Lisaftoclax in MDS that Demonstrates Potential Clinical Benefits and Favorable Safety
ROCKVILLE, Md. and SUZHOU, China , Dec. 10, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily for malignancies, today announced that it has released the follow-up safety and efficacy data of the company's investigational Bcl-2 selective inhibitor, lisaftoclax (APG-2575), in combination with azacitidine (AZA) for the treatment of patients with myelodysplastic syndrome (MDS), in a Poster Presentation at the 66th American Society of Hematology (ASH) Annual Meeting, taking place in San Diego, CA, the United States.
Live from ASH 2024 | Ascentage Pharma's Bcl-2 Inhibitor Lisaftoclax in Combinations Demonstrates Potential Clinical Benefit in Patients with Prior Exposure to Venetoclax
ROCKVILLE, Md. and SUZHOU, China , Dec. 10, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily for malignancies, today announced that it has released the latest clinical data of lisaftoclax (APG-2575) as a monotherapy or in combinations in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), in a Poster Presentation at the 66th American Society of Hematology (ASH) Annual Meeting, taking place in San Diego, CA, the United States.
Lyell Presents Positive Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the Treatment of B-cell Lymphoma at the 2024 ASH Annual Meeting
SOUTH SAN FRANCISCO, Calif., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage company advancing a pipeline of next-generation CAR T-cell therapies for patients with solid tumors or hematologic malignancies, today announced initial positive clinical data from the multi-center Phase 1-2 study of IMPT-314 in patients with large B-cell lymphoma that is being presented at the 66th American Society of Hematology (ASH) Annual Meeting. IMPT-314 is an autologous dual-targeting CD19/CD20 chimeric antigen receptor (CAR) T-cell product candidate being developed for patients with aggressive B-cell non-Hodgkin lymphoma.
Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2024
LONDON, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing next-generation programmed T cell therapies, announces an oral presentation and three poster presentations at the American Society of Hematology (ASH) Annual Meeting, being held from December 7-10, 2024, in San Diego. “Our oral presentation at ASH this year with data from the FELIX trial demonstrates that obe-cel treatment produces a high incidence of deep molecular remission in r/r adult ALL patients, which correlates with better outcomes and is associated with longer event free survival (EFS) and overall survival (OS),” said Dr. Christian Itin, Chief Executive Officer of Autolus.
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for ASH.